Nordic Nanovector ASA
Save
451.20M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia.
Similar securities
Based on sector and market capitalization
Report issue